Encision today announced that it has entered a supply agreement with Johnson & Johnson (NYSE:JNJ) subsidiary Auris Health .
Through the agreement, Auris Health will buy certain Active Electrode Monitoring technology from Encision. Boulder, Colo.-based Encision will receive an upfront payment and a milestone payment upon certain milestones. The company will also receive revenues from proprietary product sales to Auris Health.
“We are happy to be teaming up with Auris to drive new levels of patient safety in robotic surgery. Encision’s Active Electrode Monitoring is a proprietary and differentiating technology that shields patients and practitioners from radiant energy injuries during standard and robotic laparoscopic surgeries. We welcome this next phase to our relationship,” Encision president and CEO Gregory Trudel said in a news release.
Encision’s Active Electrode Monitoring was designed to prevent dangerous stray electrosurgical burns in minimally invasive surgeries.